GE HealthCare continues to make significant strides in expanding access to precision care tools and encouraging the adoption of personalized medicine worldwide. At the recent Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, the company announced several new technologies designed to meet the pressing needs of healthcare providers and patients.<\/p>\n
\u201cIt\u2019s not enough to develop cutting-edge solutions if they aren\u2019t also made more accessible to clinicians and patients around the world,\u201d shares Jean-Luc Procaccini, President & CEO, Molecular Imaging & Computed Tomography, GE HealthCare. \u201cWhile there is still much work to be done, we are proud to offer a variety of technologies that can evolve with healthcare system needs and help support a patient\u2019s entire care journey \u2013 from the systems required to create the radiotracers used to diagnose and monitor disease, to the imaging equipment used for a noninvasive look at a patient\u2019s anatomy and treatment monitoring, to the software optimized to measure lesion size and dose. In the hands of clinicians, these tools help make the practice of precision care more accessible and aim to help improve patient outcomes globally.\u201d<\/p>\n
One of the key challenges in delivering precision care is the accessibility of technologies and solutions globally. GE HealthCare aims to address this issue by offering a range of products that support the entire patient care journey.<\/p>\n
Firstly, the company introduced the MINItrace Magni, a small footprint cyclotron designed for reliable, in-house production of commercial PET tracers and radiometals. This technology, when combined with GE HealthCare’s TRACERcenter, can help physicians identify and diagnose clinical signs across various care areas, including oncology, cardiology, and neurology.<\/p>\n
Secondly, GE HealthCare expanded its Omni platform with the Omni Legend 21 cm, a performance-focused PET\/CT system that can evolve to meet growing healthcare demands. The system’s innovative 21 cm digital detector, deep learning reconstruction capabilities, and AI-powered workflow offerings enable clinicians to reduce dose while maintaining exceptional image quality.<\/p>\n
Additionally, GE HealthCare unveiled Clarify DL, a new deep-learning reconstruction technology designed to deliver clear, accurate, and effortless imaging. This AI-powered solution, developed for the StarGuide digital SPECT\/CT system, aims to reduce noise while maintaining contrast, resulting in improved diagnostic confidence.<\/p>\n
To further advance Theranostics and provide clinicians with additional digital solutions, GE HealthCare recently acquired MIM Software. The company’s full portfolio of vendor-neutral solutions offers workflow automation, flexible configuration options, and advanced features such as image fusion and dosimetry capabilities.<\/p>\n
\u201cTheranostics is awesome \u2013 it\u2019s a life extender,\u201d shares Doug, a Theranostics patient scanned on BAMF Health\u2019s StarGuide system. \u201cThis is nothing short of a miracle. I can\u2019t believe we\u2019re seeing this in our lifetime.\u201d<\/p>\n
GE HealthCare also remains committed to improving access to affordable, quality healthcare through its global refurbished medical equipment program. By extending the lifespan of equipment through technology advancements and software upgrades, the company aims to enhance clinical outcomes and stretch hospital budgets.<\/p>\n
The pursuit of increasing access to precision care for earlier, more precise, and accessible diagnosis and treatment is at the core of GE HealthCare’s mission. By offering innovative technologies, digital and AI solutions, and refurbished equipment, the company is working towards solving complex healthcare access challenges and promoting personalized patient care worldwide.<\/p>\n